

(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) EP 1 325 745 A1

(12)

**EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 158(3) EPC

(43) Date of publication:  
**09.07.2003 Bulletin 2003/28**

(51) Int Cl.7: **A61K 31/47, A61K 31/40,**  
**A61K 31/505, A61K 31/22,**  
**A61K 31/191, A61K 31/192,**  
**A61P 43/00, A61P 13/12,**  
**A61P 25/00, A61P 27/02,**  
**A61P 9/00, A61P 3/10,**  
**C07D 215/14, C07D 239/42,**  
**C07D 207/416**

(21) Application number: **01974780.7**

(22) Date of filing: **11.10.2001**

(86) International application number:  
**PCT/JP01/08921**

(87) International publication number:  
**WO 02/030425 (18.04.2002 Gazette 2002/16)**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE TR**

Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **12.10.2000 JP 2000311960**

• **SAITO, Yasushi**  
Chiba-shi, Chiba 260-0853 (JP)  
• **MORI, Sejiro**  
Chiba-shi, Chiba 260-0004 (JP)  
• **TAKEMOTO, Minoru**  
Akita-shi, Akita 010-0966 (JP)  
• **TAMAKI, Taro**  
Setagaya-ku, Tokyo 158-0094 (JP)


(71) Applicants:  
• **Nissan Chemical Industries, Ltd.**  
Chiyoda-ku, Tokyo 101-0054 (JP)  
• **Kowa Company Ltd.**  
Nagoya-shi Aichi-ken, 460-8625 (JP)

(74) Representative: **HOFFMANN - EITLE**  
Patent- und Rechtsanwälte  
Arabellastrasse 4  
81925 München (DE)

(72) Inventors:  
• **KITAHARA, Masaki**  
Shiraoka-machi, Minamisaitama (JP)

**(54) PREVENTIVES AND REMEDIES FOR COMPLICATIONS OF DIABETES**

(57) The present invention relates to the pharmaceutical useful for the prevention and the treatment of diabetic complications such as diabetic nephropathy, diabetic neuropathy, diabetic retinopathy and diabetic angiopathy among others, and to the prophylaxis and/or treatment drug for diabetic complications with the compound shown in the formula (1)



(wherein R is organic group, X is -CH<sub>2</sub>CH<sub>2</sub>- or -CH=CH-, and M is hydrogen atom, C<sub>1-10</sub> alkyl group or physiologically acceptable cation group) or its lactonized form as the active ingredient.

EP 1 325 745 A1

**Description**Technical Field

5 [0001] The present invention relates to the prophylactic and therapeutic agent with compound having inhibitory effect on 3-hydroxy-3-methylglutaryl-CoA (HMG CoA) reductase activity as the active ingredient for diabetic complications. The invention especially relates to the pharmaceutical to prevent and/or treat the onset and the progression of diabetic nephropathy, diabetic neuropathy, diabetic retinopathy and diabetic angiopathy.

Background Art

10 [0002] Diabetes mellitus is known to lead to the diabetic complications such as diabetic nephropathy, diabetic neuropathy, diabetic retinopathy or diabetic angiopathy, and the strict control of the blood glucose may be required for their prevention and treatment thereof. The fibrosis and the calcification of the tissues are often observed in these complications. Under the high blood glucose condition, glycosylated proteins which are the modulators for cell function are produced, and the accumulation of sorbitol due to the activation of intracellular polyol pathway is observed, leading to the activation of intracellular protein kinase C (PKC) which results in abnormality of glomerular cells in the kidney, nerve cells or arterial endothelial cells, and induces the accumulation of extracellular matrices and the calcification.

15 [0003] The accelerated expression of extracellular matrices such as type IV collagen or fibronectin is well documented (Cagliero E. *et al.* : *J. Clin. Invest.*, 82, 735-738 (1988), Haneda M. *et al.* : *Diabetologia*, 34, 198-200 (1991), Doi T. *et al.* : *Proc. Natl. Acad. Sci. USA*, 89, 2873-2877(1992)), but in recent days there are several papers reporting that the expression of osteopontin in the kidney and blood vessels markedly increases under diabetic condition and the expression of osteopontin thus accelerated may be in some ways related to diabetic nephropathy or diabetic angiopathy (Takemoto M. *et al.* : *Arterioscler. Thromb. Vasc. Biol.*, 20, 624-628 (2000), Takemoto M. *et al.* : *Ann. NY Acad. Sci.*, 902, 357-363 (2000)). From these findings, it is expected that the suppression of the expression of osteopontin as an extracellular matrices whose expression is accelerated in the kidney and arterial wall under the diabetic condition may be prophylactically effective on the onset or the aggravation of diabetic nephropathy or diabetic angiopathy.

20 [0004] At present, there is no pharmaceuticals discovered so far which control the essential quality of tissue lesions such as the expression and the production of extracellular matrices like osteopontin in order to prevent and/or treat diabetic complications such as diabetic nephropathy, diabetic neuropathy, diabetic retinopathy and diabetic angiopathy among others, and it is the high expectation to find pharmaceuticals having the excellent therapeutic effect for diabetic complications.


25 [0005] Hereupon, the compounds having inhibitory effect on HMG-CoA reductase activity were known to have the effects on the suppression of the cell proliferation, the suppression of cell adhesion, the suppression of intimal thickening and the prevention as well as the treatment of osteoporosis among others in addition to the main effect of inhibiting cholesterol biosynthesis. In addition, the suppression of the accumulation of fibronectin in the intimal lesion of the endothelial injury-induced neointima in the carotid artery had been reported (Kitahara M. *et al.* : *Jpn. J. Pharmacol.*, 77, 117-128 (1998). However, there has been no report on the effect of the expression of osteopontin.

30 [0006] The object of the present invention is to provide the pharmaceuticals which can prevent and/or treat diabetic complications such as diabetic nephropathy, diabetic neuropathy, diabetic retinopathy and diabetic angiopathy among others by suppressing the expression of osteopontin in the kidney and blood vessels under the diabetic condition.

Disclosure of Invention

35 [0007] Knowing the present situation as described above, the inventors of the present invention administered HMG-CoA reductase inhibitors such as the compound shown in the formula (I), namely (+)-bis((3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid)-calcium (hereafter referred as pitavastatin calcium), into streptozotocin (STZ)-induced diabetic rats and investigated the in-detail effect on the expression of osteopontin mRNA in the kidney and blood vessels. As a result, the compound shown in the formula (1) or its lactonized form thereof had shown the remarkable effect on the suppression of osteopontin mRNA expression, so the effectiveness of these compounds on the prevention and/or the treatment of diabetic complications was discovered and the present invention had been completed.

40 [0008] That is to say that the present invention is to provide the prophylactic and/or therapeutic agent for diabetic complications having the compound shown in the formula (1):



(wherein R is organic group, X is  $-\text{CH}_2\text{CH}_2-$  or  $-\text{CH}=\text{CH}-$ , and M is hydrogen atom,  $\text{C}_{1-10}$  alkyl group or physiologically acceptable cation group) or its lactonized form thereof as the active ingredient.

10

Brief Description of Drawings

**[0009]**

15 Figure 1(a) shows the effect of pitavastatin calcium on the secretion of osteopontin protein to the conditioned culture medium from aortic smooth muscle cells of rats cultured under the normal concentration of glucose, whereas Figure 1(b) shows the effect of Atorvastatin on the secretion of osteopontin protein into the conditioned culture medium from aortic smooth muscle cells of rats cultured under the normal concentration of glucose.

20 Figure 2(a) shows the influence of the addition of mevalonic acid on the suppressive effect of pitavastatin calcium on the expression of intracellular osteopontin mRNA in aortic smooth muscle cells of rats cultured under the normal concentration of glucose, whereas Figure 2(b) shows the influence of the addition of mevalonic acid on the suppressive effect of pitavastatin calcium on the secretion of osteopontin protein to the conditioned culture medium from aortic smooth muscle cells of rats cultured under the normal concentration of glucose.

25 Best Mode for Carrying Out the Invention

**[0010]** Followings are the detailed description of the present invention.

30 **[0011]** The compound shown in the formula (1) or its lactonized form thereof has been known as the compound having the inhibitory effect on HMG-CoA reductase activity, but whether these compounds have any effect on the suppression of osteopontin expression, thereby useful as the pharmaceuticals in the treatment of diabetic complications or not has been elucidated so far.

35 **[0012]** The compound shown in the formula (1) or its lactonized form thereof is described for examples in U.S. Patent No. 4,739,073 and European Patent No. 114,027; European Patent Application Laid-open No. 367,895; U.S. Patents No. 5,001,255, No. 4,613,610, No. 4,851,427, No. 4,755,606 and No. 4,808,607, No. 4,751,235, No. 4,939,159, No. 4,822,799, No. 4,804,679, No. 4,876,280, No. 4,829,081, No. 4,927,851 and No. 4,588,715; and F. G. Kathawala, Medical Research Reviews, 11, 121-146 (1991), and also European Patent Application Laid-open No. 304,063 and No. 330,057 and U.S. Patents No. 5,026,708 and No. 4,868,185; European Patent Application Laid-open No. 324,347; European Patent Application Laid-open No. 300,278; U.S. Patents No. 5,013,749, No. 5,872,130 and No. 5,856,336, U.S. Patents No. 4,231,938, U.S. Patent No. 4,444,784, U.S. Patent No. 4,346,227, U.S. Patent No. 5,354,772, U.S.

40 Patent No. 5,273,995, U.S. Patent No. 5,177,080, U.S. Patent No. 3,983,140, Japanese Patent No. 2,648,897, U.S. Patent No. 5,260,440 or Bioorganic & Medicinal Chemistry, 5, pp437, (1977) and Japanese Patent No. 2,569,746, European Patent No. 304,063 or U.S. Patent No. 5,856,336.

45 **[0013]** In particular, lovastatin in U.S. Patent No. 4,231,938, simvastatin in U.S. Patent No. 4,444,784, pravastatin in U.S. Patent No. 4,346,227, fluvastatin in U.S. Patent No. 5,354,772, atorvastatin in U.S. Patent No. 5,273,995, cerivastatin in U.S. Patent 5,177,080, mevastatin in U.S. Patent No. 3,983,140, and rosuvastatin, that is bis(+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylaminopyrimidine)-5-yl]-[3R, 5S]-dihydroxy-(E)-6-heptenoate mono-calcium in Japanese Patent No. 2,648,897, U.S. Patent No. 5,260,440 or Bioorganic & Medicinal Chemistry, 5, pp437, (1977) are respectively described. In addition, pitavastatin calcium is described in Japanese Patent No. 2,569,746, European Patent No. 304,063 or U.S. Patent No. 5,856,336.

50 **[0014]** Preferred organic group shown as R in the formula (1) above is group with the ring structure selected from indolyl, indenyl, pyridyl, pyrrolopyridyl, pyrazolopyridyl, thienopyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, indolizinyl, quinolyl, naphthyl, hexahydroronaphthyl, cyclohexyl, phenylsilylphenyl, phenylthienyl and phenylfuryl group. Especially preferred group among these cyclic organic groups are hexahydroronaphthyl, indolyl, pyridyl, pyrimidinyl, pyrrolyl and quinolyl group. These ring structures may have substituent such as hydroxyl group,  $\text{C}_{1-10}$  alkyl group (including straight chain, branched chain, cyclic group), alkoxyalkyl group, alkylcarbonyloxy group, substituted amino group, substituted sulfamoyl group, halophenyl group, and phenyl group among others, especially more preferred are those with isopropyl group, cyclopropyl group and p-fluorophenyl group. As the physiologically acceptable salts of the compound shown in the formula (1), alkali metal salts such as sodium salt, potassium salt and the likes, alkali earth metal

salts such as calcium salt, magnesium salt and the likes, organic amine salts such as phenethylamine salt and the likes, and ammonium salt are selected, but sodium salt and calcium salt are more preferred.

[0015] Furthermore, the compounds exhibiting the inhibitory effect on HMG-CoA reductase activity such as lovastatin, pravastatin, simvastatin, fluvastatin, serivastatin, atorvastatin, rosuvastatin and pitavastatin calcium among the compounds listed above are selected. Pitavastatin calcium among them is particularly preferred.

[0016] The compound shown in the formula (1) above suppresses at a statistically significant level the expression of osteopontin gene in the kidney and blood vessels of STZ-induced diabetic rats as well as the expression of osteopontin gene in the cultured vascular smooth muscle cells of rats as shown in the examples below. Therefore, the compounds shown in the formula (1) above and its lactonized form thereof are useful for the prevention and/or the treatment of diabetic complications such as diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, and diabetic angiopathy among others through the suppression of osteopontin expression. The use of the compounds of the present invention make possible not only to prevent and to treat diabetic complications brought about with accelerated expression of osteopontin in diabetic patients, but also to exploit the possibilities of the new experimental systems as well as the new screenings for pharmaceuticals among other advantages.

[0017] The administration forms in using the compounds of the present invention as the pharmaceutical are, for examples, oral administration forms such as tablet, capsule, granule, powder or syrup among others as well as parenteral administration forms such as intravenous injection, intramuscular injection, transdermal absorption, suppository, inhalation, ophthalmic solutions or collunarium among others. In addition, the active ingredient by itself can be used in order to produce the pharmaceutical preparations in these various forms, or any excipients, binders, fillers, disintegrators, surfactants, glossers, dispersion agents, buffers, preservatives, flavors, perfumes, coating agents, carriers, and diluents among others can appropriately be compounded therein.

[0018] Preferred form is the oral administration form among them, and the pH of the preparation is preferably adjusted in consideration for the stability of the active ingredient according to the methods described in Japanese Patent Application Laid-open No. Hei 2-6406, Japanese Patent No. 2,774,037, and WO97/23200.

[0019] The dose for the medical use of the present invention can be varied depending on the weight, age, gender as well as the symptoms of the patients, but 0.01 to 100mg per day, and especially 0.1 to 10mg per day of the compound shown in the formula (1) above is preferably administered in the form of once a day or twice a day for the adult in general.

#### Examples

[0020] The usefulness of the present invention is described by referring to the following examples, but the invention is not limited to the examples described herewith.

Example 1 The suppression of the expression of osteopontin mRNA in the kidney and blood vessels of streptozotocin (STZ)-induced diabetic rats

[0021] The effects of pitavastatin calcium on the expression of osteopontin mRNA in the kidney and blood vessels of STZ-induced diabetic rats were investigated according to the method described below.

[0022] Namely, 35mg per kg of body weight of STZ dissolved in the concentration of 50mg/mL of physiological saline was injected into the tail vein of male Wistar rats (body weight : about 300g), and the animals were orally administered 1mL/kg of body weight of 0.5% carboxymethylcellulose solution containing the test drug (pitavastatin calcium) in the concentration of 3mg/mL with a gastric sonde. Thereafter the oral administration was performed once a day by same volume and at fixed time during the experiment. The same volume of only 0.5% carboxymethylcellulose was given by the forced oral administration for the control group. The venous blood was withdrawn from the tail vein on the second day of the experiment and the presence of 200mg/dL or above of the blood sugar level was confirmed.

[0023] 24 hours after 7 days administration, the blood was withdrawn under the ether anesthesia, and kidneys and thoracic aorta were isolated. The predetermined amount of the tissue piece in ISOGEN (Wako Pure Chemicals K.K.) was homogenized in a polytron homogenizer and the total RNA was extracted. The total RNA thus obtained was precipitated by using isopropanol. The precipitate was washed with 70% ice cold ethanol and stored at -80°C in 70% ethanol.

[0024] Osteopontin mRNA in the total RNA obtained was detected by the conventional Northern blotting method. That is to say that the total RNA precipitated with 70% ethanol was subjected to centrifugation at 15000 rpm, the precipitate was dried at room temperature after decanting the supernatant and dissolved in a small amount of TE buffer (10mM Tris-HCl buffer-1mM EDTA solution). 10µL out of the solution thus obtained was diluted with 990µL of TE buffer solution, and the amount of RNA was calculated by measuring the absorbance at 260nm ultraviolet light of the solution. 40% solution of deionized glyoxal (3.5µL), 0.1M of NaHPO<sub>4</sub> buffer solution (2.4µL) and dimethylsulfoxide (11.8µL) were added to the predetermined amount (10 or 20 µg) of the total RNA (final volume : 6µL), heated at 50°C for 1 hour and the total RNA was denatured. 6.3µL of 10mM sodium phosphate buffer solution (pH : 6.8) containing 50% glycerol and

0.4% bromophenol blue was added to the solution after the solution was cooled to the room temperature, and then RNA was subjected to electrophoresis using 1.5% agarose gel. RNA was blotted from agarose to nylon membrane in a conventional fashion by using 20X saline-sodium citrate (SSC). The blotted nylon membrane was washed with 2X SSC, and RNA was fixed on the nylon membrane by heating it to 80°C in vacuo. DNA fragment encoding osteopontin was digested from pCRII<sup>®</sup>IrOP vector with Eco R1 endonuclease and purified with Probe Quant<sup>™</sup> G-50 Micro Columns (Amersham Pharmacia Biotech Co. Ltd.). DNA fragment encoding Osteopontin thus obtained was hybridized for overnight together with the nylon membrane at 65°C with Rediprime<sup>™</sup> II (Amersham Pharmacia Biotech Co. Ltd.) radioactive probe labeled with <sup>32</sup>P radioisotope. Radioisotope level of the probe bound to the nylon membrane was detected on the X-ray film and the density of the bands were analyzed according to NIH Image. 18S tRNA was used as the RNA internal standard and the amount of the expression was represented with the comparative intensities of the density of the bands. Osteopontin mRNA was similarly measured in the normal rat experiment.

[0025] The results of Example 1 are shown in Table 1.

[0026] In Table 1, OPN mRNA/18S represents the ratio of the density of osteopontin mRNA to the density of 18S tRNA based on the NIH Image Analysis and % inhibition represents that to the respective control groups. The values of OPNmRNA/18S are mean  $\pm$  standard deviation.

Table 1

	Kidney		Aorta	
	OPNmRNA/18S	% Inhibition	OPNmRNA/18S	% Inhibition
Healthy control	1.343 $\pm$ 0.462		2.400 $\pm$ 1.345	
Healthy with drug administration	1.667 $\pm$ 0.321	-24.1	2.433 $\pm$ 0.929	-1.4
Diabetics control	3.233 $\pm$ 0.115		3.200 $\pm$ 0.361	
Diabetics with drug administration	1.933 $\pm$ 0.874*	40.2	1.300 $\pm$ 0.781**	59.4

\* : significantly different from the control; p=0.016

\*\* : significantly different from the control; p=0.036

OPN : osteopontin

[0027] The ratio of osteopontin mRNA in the kidney and the aorta to 18S tRNA increased from 1.343 to 3.233 and 2.400 to 3.200 respectively in streptozotocin-induced diabetic rats. Pitavastatin calcium did not influence the expression of osteopontin in the kidney and the aorta of healthy rats (1.667 and 2.433 respectively), but decreased with the statistical significance the amount of the expression of osteopontin mRNA in the kidney and the aorta of STZ-induced diabetic rats to 1.933 (inhibition rate : 40.2%) and to 1.300 (inhibition rate : 59.4%), respectively.

Example 2 The suppression of the secretion of osteopontin protein in aortic smooth muscle cells of rats

[0028] The effect of pitavastatin calcium and atorvastatin on the secretion of osteopontin protein into the conditioned culture medium from aortic smooth muscle cells of rats cultured under the normal glucose concentration were measured according to the method described below.

[0029] At first, aortic smooth muscle cells of rats (5 to 10 passage culture) were seeded in a 6-well culture plate and the confluent cultures were attained by culturing in low glucose (1000mg/L) Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS : BioWhittaker Co. Ltd.) under 5% CO<sub>2</sub> atmosphere at 37°C. Thereafter, the medium was replaced with the medium with the test drugs (pitavastatin calcium and atorvastatin) and the cells were cultured for 48 hours. After the medium was again replaced with 1.5mL of FBS-free medium per well, the cells were cultured for additional 48 hours and the conditioned media were collected. The equal amount of 0.14M NaCl in 50mM Tris hydrochloride buffer solution (pH 7.4) was added to the predetermined volume (0.5-1mL) of the conditioned medium, and then 50 $\mu$ L of anion exchange DEAE cellulose ; DE52 (Whatman Co. Ltd.) suspended at 50% concentration after swelling and equilibrated with the same buffer described above was added, stirred gently for 1 hour at 4°C, and osteopontin protein was absorbed on DE52.

[0030] After centrifugation, sedimented DE52 gels were washed several times with the same buffer, and 60 $\mu$ L of 0.2M Tris hydrochloride buffer solution (pH 6.8) containing 5% of 2-mercaptoethanol, 4% of SDS, 5mL of EDTA, 20% of glycerol and 0.01% of bromophenol blue was added, and heat-treated for 5 minutes at 95°C. After cooling to the room temperature, the suspension was centrifuged and the predetermined amount (30 $\mu$ L) of the supernatant was subjected to 10% SDS polyacrylamide gel electrophoresis. After electrophoresis, proteins were transferred on nitrocellulose membrane according to the conventional technique and the Western blotting according to the conventional method was conducted. Namely, the nitrocellulose membrane was shaken in TBS-T (Tris buffer-physiological saline solution containing 0.2% Tween-20) with 3% bovine serum albumin for over 1 hour and the membrane was subse-

quently exposed with the same buffer described above containing anti-osteopontin antibody (MP IIIB10<sub>1</sub>; American Research Products Co. Ltd.) at 1/1000 dilution for 1 hour with shaking. After that, the membrane was shaken for 1 hour in the horseradish peroxidase bound anti-mouse IgG antibody solution diluted to 1/5000 with TBS-T containing 3% bovine serum albumin and then washed with TBS-T for several times. Chemiluminescences were detected on X-ray film using ECL™ (Amersham Pharmacia Biotech Co. Ltd.). The density of the bands were analyzed according to NIH Image.

[0031] The above measurements were carried out with the concentration of 0μM (control), 0.03μM and 0.3μM for pitavastatin calcium, and with the concentrations of 0μM (control), 0.3μM and 3μM for atorvastatin, respectively.

[0032] The results of Example 2 were shown in Figure 1.

[0033] The density of osteopontin protein measured with NIH Image Analysis for various concentration of pitavastatin calcium are shown in Figure 1(a), and the density of osteopontin protein measured with NIH Image Analysis for various concentration of atorvastatin are shown in Figure 1(b).

[0034] It is clear from Figure 1 that both pitavastatin calcium and atorvastatin inhibited with the statistical significance the amount of the secretion of osteopontin protein into the conditioned medium from the cultured aortic smooth muscle cells of rats.

Example 3 The effect of mevalonic acid on the expression of osteopontin mRNA and the suppression of the secretion of osteopontin protein in aortic smooth muscle cells of rats

[0035] The effect of mevalonic acid on the suppression with pitavastatin calcium for the expression of osteopontin mRNA and the secretion of osteopontin protein in aortic smooth muscle cells of rats were measured according to the method described below.

[0036] Aortic smooth muscle cells of rats (5 to 10 passage culture) were seeded in a 6-well culture plate and the confluent cultures were attained by culturing in low glucose (1000mg/L) DMEM with 10% FBS under 5% CO<sub>2</sub> atmosphere at 37°C. Thereafter, the medium was replaced with the medium with pitavastatin calcium (8μM) and/or mevalonic acid (100μM), and the cells were cultured for another 48 hours. The medium was again replaced with 1.5mL of FBS-free medium per well, and the cells were cultured further for 48 hours.

[0037] After the cultivation, the cells adhered to the culture plate were homogenized together with ISOGEN, RNA were extracted exactly as in Example 1, and the amount of osteopontin mRNA was analyzed by northern blotting method.

[0038] At the same time, the conditioned medium was collected, osteopontin protein was absorbed on DE52, subjected to electrophoresis exactly as in Example 2, and the amount of the secreted osteopontin protein was analyzed by western blotting method.

[0039] The above measurements were carried out in the three cases when pitavastatin calcium and mevalonic acid were not added, when only pitavastatin calcium was added, and when both pitavastatin calcium and mevalonic acid were added.

[0040] The results of Example 3 were shown in Figure 2.

[0041] Figure 2(a) shows the ratio of the density of osteopontin mRNA band to the density of 18S tRNA band according to NIH Image Analysis, and Figure 2(b) shows the density of osteopontin protein according to NIH Image Analysis for three conditions described above.

[0042] Although pitavastatin calcium suppresses both the expression of osteopontin mRNA and the secretion of osteopontin protein from cultured smooth muscle cells of rats, it is clear from Figure 2 that these suppressive effect with pitavastatin calcium disappear with the addition of mevalonic acid. From the fact, it is found that the addition of pitavastatin calcium suppresses the production of mevalonic acid, thereby suppressing the expression of osteopontin mRNA as well as the secretion of protein thereof in aortic smooth muscle cells.

#### Industrial Applicability

[0043] The compound of the present invention shown in the formula (1) shows the specific and effective inhibitory action against the accelerated expression of osteopontin in the kidney and the aorta afflicted with diabetic condition without affecting the expression of osteopontin under healthy condition, and markedly suppresses the biosynthesis of osteopontin in these organs in diabetes.


[0044] Therefore, the compound shown in the formula (1) is especially useful as prophylaxis and/or treatment drug for diabetic complications possibly brought about by the accelerated expression of osteopontin gene such as diabetic nephropathy, diabetic neuropathy, diabetic retinopathy and diabetic angiopathy among others.

## Claims

1. A prophylaxis and/or treatment drug for diabetic complications comprising compound shown in the formula (1)

5

10



(wherein R is organic group, X is  $-\text{CH}_2\text{CH}_2-$  or  $-\text{CH}=\text{CH}-$ , and M is hydrogen atom,  $\text{C}_{1-10}$  alkyl group or physiologically acceptable cation group) or its lactonized form as the active ingredient.

15 2. A prophylaxis and/or treatment drug for diabetic complications according to claim 1, wherein R is group with the ring structure selected from indolyl, indenyl, pyridyl, pyrrolopyridyl, pyrazolopyridyl, thienopyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, indolizinyl, quinolyl, naphthyl, hexahydronaphthyl, cyclohexyl, phenylsilylphenyl, phenylthienyl and phenylfuryl group.

20 3. A prophylaxis and/or treatment drug for diabetic complications according to claim 2, wherein the compound shown in the formula (1) is lovastatin, pravastatin, simvastatin, fluvastatin, serivastatin, atorvastatin, rosuvastatin or (+)-bis{(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid}-calcium.

25 4. A prophylaxis and/or treatment drug for diabetic complications according to claim 3, wherein the compound shown in the formula (1) is (+)-bis{(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid}-calcium.

30

35

40

45

50

55

FIG. 1





FIG. 2



INTERNATIONAL SEARCH REPORT		International application No. PCT/JP01/08921												
<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int.Cl <sup>7</sup> A61K31/47, 31/40, 31/505, 31/22, 31/191, 31/192, A61P43/00, 13/12, 25/00, 27/02, 9/00, 3/10, C07D215/14, 239/42, 207/416														
According to International Patent Classification (IPC) or to both national classification and IPC														
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) Int.Cl <sup>7</sup> A61K31/47, 31/40, 31/505, 31/22, 31/191, 31/192, C07D251/14, 239/42, 207/416														
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched														
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CA (STN), REGISTRY (STN), WPIDS (STN)														
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left; padding: 2px;">Category*</th> <th style="text-align: left; padding: 2px;">Citation of document, with indication, where appropriate, of the relevant passages</th> <th style="text-align: left; padding: 2px;">Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; padding: 2px;">X</td> <td style="text-align: left; padding: 2px;">WO 00/45818 A (ASTRAZENECA UK LIMITED), 10 August, 2000 (10.08.00), Claims 1,5 etc., &amp; EP 1150678 A</td> <td style="text-align: center; padding: 2px;">1-3 4</td> </tr> <tr> <td style="text-align: center; padding: 2px;">Y</td> <td style="text-align: left; padding: 2px;">JP 4-282324 A (E.R. Squibb and Sons Inc.), 07 October, 1992 (07.10.92), Claims 1,3 etc., &amp; US 4005113 A</td> <td style="text-align: center; padding: 2px;">1-3 4</td> </tr> <tr> <td style="text-align: center; padding: 2px;">Y</td> <td style="text-align: left; padding: 2px;">WO 00/05213 A (Nissan Chemical Industries, Ltd.), 03 February, 2000 (03.02.00), p. 3., etc., &amp; EP 1099694 A</td> <td style="text-align: center; padding: 2px;">4</td> </tr> </tbody> </table>			Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X	WO 00/45818 A (ASTRAZENECA UK LIMITED), 10 August, 2000 (10.08.00), Claims 1,5 etc., & EP 1150678 A	1-3 4	Y	JP 4-282324 A (E.R. Squibb and Sons Inc.), 07 October, 1992 (07.10.92), Claims 1,3 etc., & US 4005113 A	1-3 4	Y	WO 00/05213 A (Nissan Chemical Industries, Ltd.), 03 February, 2000 (03.02.00), p. 3., etc., & EP 1099694 A	4
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
X	WO 00/45818 A (ASTRAZENECA UK LIMITED), 10 August, 2000 (10.08.00), Claims 1,5 etc., & EP 1150678 A	1-3 4												
Y	JP 4-282324 A (E.R. Squibb and Sons Inc.), 07 October, 1992 (07.10.92), Claims 1,3 etc., & US 4005113 A	1-3 4												
Y	WO 00/05213 A (Nissan Chemical Industries, Ltd.), 03 February, 2000 (03.02.00), p. 3., etc., & EP 1099694 A	4												
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "B" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 09 November, 2001 (09.11.01)		Date of mailing of the international search report 04 December, 2001 (04.12.01)												
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer												
Facsimile No.		Telephone No.												

Form PCT/ISA/210 (second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/08921

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:

2.  Claims Nos.: 1  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

See extra sheet.

3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest  The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/08921

Continuation of Box No.I-2 of continuation of first sheet(1)

Even though the statement in the description is examined, the structural scope of the term "organic group" as described in claim 1 cannot be clarified. Thus, the scope of the drug according to the present invention is unclear.

Accordingly, claim 1 and the description fail to satisfy the defined requirement to such an extent as enabling any meaningful international search.

In this international search report, prior art documents have been examined on the basis of the compounds particularly cited in the description.